â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
CHECK 3: PRECLINICAL FRAMING
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

LAW / STANDARD BEING CHECKED:

  When a company presents preclinical (animal or in vitro) data,
  the SEC requires that it NOT state or imply that the data
  demonstrates clinical (human) safety or efficacy. "Safety and
  efficacy determinations are solely within the authority of the
  FDA." Preclinical data may be presented as objective results
  (e.g., "tumor volume decreased 40% in the mouse model"), but
  not with conclusions about what those results mean for humans
  (e.g., "this demonstrates that our drug is effective").

  Two distinct sub-issues:

  (A) PRECLINICAL-TO-CLINICAL LEAP: Claiming or implying that
      animal/in vitro results predict human outcomes. The SEC
      requires a translation-risk caveat ("preclinical results
      may not be predictive of clinical results").

  (B) MECHANISM-OF-ACTION OVERCLAIMING: Stating that the drug
      "inhibits", "activates", "blocks" a target as proven fact
      when the evidence is only preclinical. The SEC permits
      hypothetical framing ("designed to inhibit", "intended to
      activate") but challenges factual framing unless supported
      by human clinical data.

  Rule 408 (17 C.F.R. Â§ 230.408): "such further material
  information ... as may be necessary to make the required
  statements ... not misleading."


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
SOURCES / AUTHORITIES â€” SEC COMMENT LETTERS + CHALLENGED S-1 TEXT
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

COMPARISON PAIR 1: CURANEX PHARMACEUTICALS (S-1, filed Jun. 20, 2024)

  S-1 TEXT THAT WAS CHALLENGED:

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/Archives/edgar/data/2025942/
    000149315224041335/forms-1.htm

    Known from comment letter: S-1 stated "Phyto-N has
    demonstrated promising efficacy in animal models and has a
    long history of safe use in traditional medicine."

    Also: "Phyto-N boasts superior anti-inflammatory properties
    and unlike recently FDA approved Rezdiffra, Phyto-N mitigates
    inflammation occurrence without causing adverse reaction, such
    as diarrhea, nausea, and potential liver enzyme elevations."

    NEED: Full surrounding paragraphs for both passages, with
    section headers and page numbers.]

  SEC COMMENT LETTER #1 (Jul. 17, 2024):

    "You state that your lead product candidate, Phyto-N, has
    demonstrated promising efficacy in animal models and has a
    long history of safe use in traditional medicine. Safety and
    efficacy determinations are solely within the authority of the
    FDA or comparable foreign regulator. Please revise or remove
    statements/inferences throughout your prospectus that your
    product candidate is safe and/or effective."

  SEC COMMENT LETTER #2 (Jul. 17, 2024 â€” same letter, separate
  comment):

    "You state that Phyto-N boasts superior anti-inflammatory
    properties and unlike recently FDA approved Rezdiffra, Phyto-N
    mitigates inflammation occurrence without causing adverse
    reaction, such as diarrhea, nausea, and potential liver enzyme
    elevations. Please discuss your basis for such claims."

  WHAT THE SEC CHALLENGED:
  - Comment #1: "promising efficacy" (preclinical data presented
    as if it establishes efficacy) + "safe use in traditional
    medicine" (implying safety without FDA determination).
  - Comment #2: Comparative superiority claim against an FDA-
    approved drug (Rezdiffra) â€” preclinical company claiming its
    drug "mitigates inflammation without causing adverse reaction"
    compared to an approved drug. This straddles both Check 3
    (preclinical overclaiming) and Check 4 (comparative claims).

  KEY PATTERN: Curanex was entirely preclinical â€” no IND filed,
  no human data. The S-1 used animal model data to make claims
  that read as if the drug's efficacy and safety were established.
  This is the most aggressive version of the preclinical framing
  violation: treating animal data as proof.

  SOURCE: https://www.sec.gov/Archives/edgar/data/2025942/
  000000000024008116/filename1.pdf


COMPARISON PAIR 2: VIRPAX PHARMACEUTICALS (S-1, filed ~2020;
S-1/A filed Feb. 2024)

  S-1 TEXT THAT WAS CHALLENGED:

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/Archives/edgar/data/1708331/
    000101376224002110/ea0209752-s1_virpaxphar.htm

    Known from comment letter: S-1 stated:
    (a) "early animal studies indicate that Probudur may provide
    pain control for up to 96 hours"
    (b) "NES100 has demonstrated comparable preclinical activity to
    morphine in all animal pain models without the drug seeking,
    respiratory depression and tolerance associated with opioids"

    NEED: Full surrounding paragraphs, section headers, pages.]

  SEC COMMENT LETTER (Sep. 4, 2020):

    "We note your disclosure that early animal studies indicate
    that Probudur may provide pain control for up to 96 hours. We
    note also your statement on page 3 that NES100 has
    demonstrated comparable preclinical activity to morphine in
    all animal pain models without the drug seeking, respiratory
    depression and tolerance associated with opioids. Please
    revise these and similar statements throughout your
    registration statement that state or imply that your product
    candidates are safe or effective as these determinations are
    solely within the authority of the FDA and comparable foreign
    regulators."

  WHAT THE SEC CHALLENGED:
  - "indicate that Probudur may provide pain control" â€” animal
    studies being presented as indicating a clinical outcome.
    Even "may" doesn't cure it; the leap is from animal â†’ human.
  - "demonstrated comparable preclinical activity to morphine...
    without the drug seeking, respiratory depression" â€” this is
    double: (a) preclinical result stated as demonstration of
    clinical-grade activity, and (b) comparative claim against
    morphine without head-to-head human data.

  KEY PATTERN: Virpax used hedging ("may provide", "preclinical
  activity") but the SEC still challenged it because the overall
  framing implied the animal data predicted human outcomes. The
  word "demonstrated" was particularly problematic â€” it implies
  the result is established fact, not a preclinical signal.

  SOURCE: SEC comment letter to Virpax, Sep. 4, 2020
  (EDGAR correspondence files)


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
THE UNDERLYING SEC CONCERN (synthesized):
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  1. ONLY the FDA determines safety and efficacy. An S-1 cannot
     state or imply that preclinical data establishes either one.

  2. Animal model results are NOT evidence of human outcomes.
     They are evidence that the drug warrants further study. The
     S-1 may present the data objectively (measurements, p-values,
     tumor volume reductions) but cannot draw efficacy or safety
     conclusions from them.

  3. "Demonstrated" is a trigger word. When used with preclinical
     data, it implies the drug has proven something. Compare:
     - CHALLENGED: "NES100 has demonstrated comparable activity
       to morphine" (implies proof)
     - PERMITTED: "In preclinical studies, NES100 showed activity
       in pain models. These preclinical results may not be
       predictive of results in clinical trials." (objective
       result + translation caveat)

  4. Traditional medicine history does NOT establish safety.
     "Long history of safe use" implies a safety determination
     that only the FDA can make.

  5. Mechanism-of-action language:
     - PERMITTED: "ARD-101 is designed to activate the GLP-1
       receptor" (hypothetical)
     - CHALLENGED: "ARD-101 activates the GLP-1 receptor"
       (factual) â€” unless supported by human clinical data
       showing receptor engagement.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
HOW THIS CHECK WAS PROCESSED:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  Script: s1_parser.py â†’ _scan_preclinical_framing()

  STEP A â€” PRECLINICAL INDICATOR SCAN:
  Regex PRECLINICAL_RE matches: "animal model", "in vivo",
  "in vitro", "preclinical", "mouse", "rat", "murine",
  "xenograft", "cell line", "ex vivo"
  â†’ Returns all passages containing preclinical indicators.

  STEP B â€” TRANSLATION-RISK CAVEAT CHECK:
  For each preclinical passage, checks within 500 chars for:
  - "may not predict" / "may not be predictive"
  - "no assurance" / "cannot guarantee"
  - "preclinical results may not be indicative"
  - "results in animal models may not translate"
  If caveat found â†’ passage marked CAVEATED.
  If no caveat â†’ passage marked UNCAVEATED â†’ potential escalation.

  STEP C â€” VERB CLASSIFICATION:
  For each preclinical passage, classify MoA verbs:
  - FACTUAL: "inhibits", "activates", "blocks", "has shown",
    "demonstrated", "established", "proven"
  - HYPOTHETICAL: "designed to", "intended to", "may",
    "potentially", "aims to"
  If FACTUAL verb + preclinical context + no human data citation
  â†’ FLAG for escalation.

  STEP D â€” CONTEXT ENRICHMENT:
  For flagged passages, check whether the S-1 has human clinical
  data for the same drug-target claim elsewhere. If the company
  has Phase 2 data showing receptor engagement, then "activates
  the GLP-1 receptor" is supported by human data, not just
  preclinical.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
S-1 TEXT FOUND [FOR THE S-1 UNDER REVIEW]:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  114 preclinical references found across all candidate passages.
  3 translation-risk caveat patterns present in Risk Factors.

  MoA language: "has shown" appears in context of the company's
  own Phase 2a clinical trial results â€” NOT purely preclinical
  claims. The factual verb is supported by human data.

  [Example passages should be quoted here with section/page â€”
  PLACEHOLDER for actual AARD S-1 text.]

  Assessment: Preclinical references have translation caveats.
  MoA claims supported by clinical data. No uncaveated
  preclinical-to-clinical leaps detected.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
ESCALATION TRIGGERS:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  TRIGGER 1: Preclinical efficacy/safety claim WITHOUT nearby
  translation caveat â†’ ESCALATE.

  TRIGGER 2: "Demonstrated" + preclinical context + no human
  data supporting the claim â†’ ESCALATE.

  TRIGGER 3: "History of safe use" / "long track record of
  safety" without FDA approval â†’ ESCALATE.

  TRIGGER 4: Factual MoA verb + preclinical-only evidence â†’
  ESCALATE.

  NO TRIGGER: All preclinical claims caveated, MoA claims
  supported by clinical data â†’ GREEN.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
SATISFIED: Yes â€” no escalation needed.
STATUS: ğŸŸ¢ GREEN
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ESCALATION PROMPT DESIGN â€” CHECK 3
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

Fires when any trigger above is met. Multi-step structure.

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 1: PASSAGE ANALYSIS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

SYSTEM CONTEXT:
  You are reviewing an S-1 registration statement for compliance
  with SEC standards on preclinical data presentation. The SEC's
  position is that "safety and efficacy determinations are solely
  within the authority of the FDA." You will analyze flagged
  passages against actual SEC comment letters.

SLOT 1 â€” FLAGGED S-1 PASSAGES:
  [Each passage flagged by code scanner, with:
  - Full 400-char context
  - Section name and page
  - Why it was flagged (uncaveated preclinical claim, factual
    MoA verb, etc.)
  - Whether human clinical data exists for same drug/target
    elsewhere in the S-1]

SLOT 2 â€” SEC COMMENT LETTER COMPARISON PAIRS:

  PAIR 1 â€” CURANEX (preclinical company, no human data):
  CHALLENGED TEXT: "Phyto-N has demonstrated promising efficacy
  in animal models and has a long history of safe use in
  traditional medicine."
  SEC RESPONSE: "Safety and efficacy determinations are solely
  within the authority of the FDA or comparable foreign regulator.
  Please revise or remove statements/inferences throughout your
  prospectus that your product candidate is safe and/or
  effective."

  PAIR 2 â€” VIRPAX (preclinical, hedged language still challenged):
  CHALLENGED TEXT: "early animal studies indicate that Probudur
  may provide pain control for up to 96 hours" AND "NES100 has
  demonstrated comparable preclinical activity to morphine in all
  animal pain models without the drug seeking, respiratory
  depression and tolerance associated with opioids."
  SEC RESPONSE: "Please revise these and similar statements
  throughout your registration statement that state or imply that
  your product candidates are safe or effective as these
  determinations are solely within the authority of the FDA."

SLOT 3 â€” STRUCTURED ANALYSIS QUESTIONS:

  For each flagged passage, answer:

  (a) CLAIM TYPE: Is this a preclinical efficacy claim, a
      preclinical safety claim, or a mechanism-of-action claim?

  (b) DATA SUPPORT: Is the claim supported by:
      - Preclinical data only (animal/in vitro) â†’ HIGH RISK
      - Human clinical data from the company's own trials â†’ LOW RISK
      - Published literature on the target/mechanism â†’ MEDIUM RISK

  (c) TRANSLATION CAVEAT: Is there a caveat within 500 chars
      stating that preclinical results may not predict clinical
      outcomes? If yes, quote it. If no, note its absence.

  (d) VERB ANALYSIS: Does the passage use factual verbs
      ("demonstrated", "established", "proven", "has shown") or
      hypothetical verbs ("designed to", "intended to", "may")?
      If factual: is the factual claim supported by human data?

  (e) COMPARISON TO CHALLENGED LANGUAGE: Is this passage
      materially similar to the Curanex or Virpax passages that
      the SEC challenged? Key comparisons:
      - Curanex: "demonstrated promising efficacy in animal
        models" â€” does the target S-1 use similar language?
      - Virpax: "has demonstrated comparable preclinical activity"
        â€” does the target S-1 treat preclinical data as proof?
      - Curanex: "long history of safe use" â€” does the target
        S-1 imply safety from non-FDA sources?

  (f) SEVERITY: On the Curanex-to-Virpax spectrum:
      - CURANEX-LIKE: Preclinical data stated as proof of
        efficacy/safety, no hedging (MOST AGGRESSIVE)
      - VIRPAX-LIKE: Hedged but still implying clinical
        prediction from animal data (MODERATELY AGGRESSIVE)
      - BORDERLINE: Factual verb but with nearby caveat and
        clinical data support (LEAST AGGRESSIVE)

REQUIRED OUTPUT FORMAT (Step 1):

  {
    "passages_analyzed": [
      {
        "passage_id": 1,
        "section": "[section name]",
        "page_approx": "[page]",
        "claim_type": "PRECLINICAL_EFFICACY" | "PRECLINICAL_SAFETY"
          | "MECHANISM_OF_ACTION",
        "data_support": "PRECLINICAL_ONLY" | "HUMAN_CLINICAL"
          | "PUBLISHED_LITERATURE",
        "translation_caveat_present": true | false,
        "caveat_text": "[quoted]" | null,
        "verb_type": "FACTUAL" | "HYPOTHETICAL",
        "factual_verb_supported_by_human_data": true | false | null,
        "closest_comparison_pair": "CURANEX" | "VIRPAX",
        "similarity_to_challenged": "MATERIALLY_SIMILAR" |
          "DISTINGUISHABLE" | "MORE_AGGRESSIVE",
        "severity": "CURANEX_LIKE" | "VIRPAX_LIKE" | "BORDERLINE",
        "reasoning": "[2-3 sentences]"
      }
    ],
    "total_flagged": 0,
    "curanex_like_count": 0,
    "virpax_like_count": 0,
    "borderline_count": 0,
    "step1_assessment": "CLEAR" | "CONCERN" | "SIGNIFICANT_CONCERN"
  }


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 2: WEB SEARCH AUGMENTATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  SEARCH QUERIES:
  1. "SEC comment letter preclinical efficacy safety biotech 2024
     2025"
  2. "SEC comment letter demonstrated animal model S-1"

  PURPOSE: Check for recent enforcement patterns. Has the SEC
  become stricter on preclinical framing? Any recent comment
  letters addressing the same "demonstrated" verb pattern?

  OUTPUT: Same format as Check 2 Step 2.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 3: FINAL STATUS DETERMINATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  DECISION TREE:

  IF step1_assessment = "CLEAR":
    â†’ ğŸŸ¢ GREEN

  IF step1_assessment = "CONCERN":
    IF all flagged passages are BORDERLINE severity:
      â†’ ğŸŸ¡ YELLOW
      â†’ Narrative: "Preclinical data uses factual verb but has
        nearby caveat and clinical data support. Less aggressive
        than Curanex/Virpax patterns. Attorney review recommended
        to confirm factual verbs are adequately supported."
    ELSE:
      â†’ ğŸŸ¡ YELLOW or ğŸ”´ RED depending on count

  IF step1_assessment = "SIGNIFICANT_CONCERN":
    IF curanex_like_count > 0:
      â†’ ğŸ”´ RED
      â†’ Narrative: "[N] passages present preclinical data as
        proof of efficacy/safety, matching the pattern the SEC
        challenged in Curanex ('demonstrated promising efficacy
        in animal models'). No translation caveat. No human data
        support. SEC has consistently required revision."
    ELSE:
      â†’ ğŸŸ¡ YELLOW

  OUTPUT: Same JSON format as Check 2 Step 3.


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
CHECK 4: COMPARATIVE CLAIMS
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

LAW / STANDARD BEING CHECKED:

  When a company compares its drug favorably to competitors or
  existing treatments, the SEC requires either (a) head-to-head
  clinical data supporting the comparison, or (b) removal of the
  claim. Critically, qualifying language ("we believe", "we
  expect", "potential") does NOT cure the problem â€” the SEC has
  explicitly said so in the Zenas letter.

  The SEC's concern is two-fold:

  (1) CLINICAL SUPERIORITY CLAIMS: "best-in-class", "superior",
      "safer", "more effective" â€” these imply the drug is better
      than alternatives, which is a clinical determination only
      the FDA can make.

  (2) COMPARATIVE FRAMING WITHOUT DATA: Describing the drug in
      comparison to specific competitors without head-to-head
      trial data. Even if the comparison is mechanistic ("our
      drug targets X while competitors target Y"), if the framing
      implies clinical advantage, the SEC challenges it.

  Rule 408 (17 C.F.R. Â§ 230.408): Material information must not
  be misleading. A comparison implying superiority without data
  is misleading.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
SOURCES / AUTHORITIES â€” SEC COMMENT LETTERS + CHALLENGED S-1 TEXT
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

COMPARISON PAIR 1: NUVALENT (S-1, filed Jul. 6, 2021)

  S-1 TEXT THAT WAS CHALLENGED (pages 3, 118, 130):

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/Archives/edgar/data/1861560/
    000119312521209001/d174530ds1.htm

    Known from comment letter: S-1 used "potential best-in-class
    product candidate[s]" on pages 3, 118, and 130 to describe
    NVL-520 and NVL-655. Company was preclinical at time of
    filing â€” neither candidate had entered human trials.

    NEED: Full surrounding paragraphs for each of the three page
    references, with section headers.]

  SEC COMMENT LETTER (Jun. 25, 2021):

    "We note your statement on pages 3, 118, 130 and elsewhere
    in the prospectus that your lead product candidates are
    'potential best-in-class product candidate[s].' The term
    'best-in-class' suggests that the product candidates are
    effective and likely to be approved as a therapy for the
    treatment of NSCLC and other advanced cancers. Given the
    early stage of development of NVL-520 and NVL-655, it is
    not appropriate to suggest that this product is likely to be
    effective or receive regulatory approval. Please delete these
    references throughout your registration statement."

  WHAT THE SEC CHALLENGED:
  - "best-in-class" = implies the drug IS the best among existing
    therapies. Even "potential best-in-class" didn't cure it.
  - Preclinical company making comparative superiority claims
    without ANY human data, let alone head-to-head trials.
  - SEC required DELETION, not revision â€” no amount of hedging
    would fix this.

  KEY PATTERN: "Potential" does NOT cure "best-in-class." The SEC
  treated "potential best-in-class" identically to "best-in-class."

  SOURCE: SEC comment letter to Nuvalent, Jun. 25, 2021


COMPARISON PAIR 2: ZENAS BIOPHARMA (S-1, filed ~May 2024)

  S-1 TEXT THAT WAS CHALLENGED:

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/Archives/edgar/data/1953926/
    000110465924091950/tm2332800-11_s1.htm

    Known from comment letter: S-1 claimed obexelimab is "safer"
    and "more effective" than anti-CD20 or other anti-CD19
    targeting therapies. Company used qualifying language ("we
    believe") but SEC said this does not address the concern.

    NEED: Full surrounding paragraphs with section/page.]

  SEC COMMENT LETTER (May 15, 2024):

    "We note statements here, and throughout the prospectus,
    claiming that obexelimab is 'safer' and 'more effective' than
    anti-CD20 or other anti-CD19 targeting therapies. Please note
    that conclusions of safety and efficacy are within the sole
    authority of the FDA and comparable foreign regulators.
    Qualifying language that statements of safety and efficacy are
    expressions of the company's beliefs or expectations do not
    address this concern. Please revise these statements or remove
    them."

  WHAT THE SEC CHALLENGED:
  - "safer" and "more effective" = direct comparative claims
    requiring head-to-head data.
  - CRITICAL HOLDING: "Qualifying language that statements of
    safety and efficacy are expressions of the company's beliefs
    or expectations DO NOT ADDRESS THIS CONCERN." This is the
    SEC explicitly rejecting the "we believe" defense. This is
    the most important sentence in any of the comparison pair
    comment letters.

  KEY PATTERN: "We believe our drug is safer" is NOT a cure.
  The SEC treats it identically to "our drug is safer."

  SOURCE: SEC comment letter to Zenas BioPharma, May 15, 2024


COMPARISON PAIR 3: KHOSLA/VALO HEALTH (S-4, filed ~Jul. 2021)

  S-1 TEXT THAT WAS CHALLENGED:

    [PLACEHOLDER â€” FETCH S-4 TEXT.

    Known from comment letter: S-4 compared VLO-017 to S1P1R
    functional antagonists without head-to-head clinical data.

    NEED: Full surrounding paragraphs with context.]

  SEC COMMENT LETTER (Jul. 28, 2021):

    "Please remove the comparison to S1P1R functional antagonists
    unless these antagonists were included in a head-to-head
    clinical trial."

  WHAT THE SEC CHALLENGED:
  - Mechanistic comparison to a specific drug class without
    head-to-head data. Even if the comparison is about mechanism,
    not clinical outcome, the SEC required either data or removal.

  KEY PATTERN: The SEC's concern extends beyond "safer" and "more
  effective" â€” it includes MECHANISTIC comparisons to specific
  named competitors when framed to imply clinical advantage.

  SOURCE: SEC comment letter to Khosla/Valo Health, Jul. 28, 2021


ADDITIONAL AUTHORITY â€” CURANEX (straddles Check 3 + Check 4):

  SEC COMMENT LETTER #2 (Jul. 17, 2024):

    "You state that Phyto-N boasts superior anti-inflammatory
    properties and unlike recently FDA approved Rezdiffra, Phyto-N
    mitigates inflammation occurrence without causing adverse
    reaction, such as diarrhea, nausea, and potential liver enzyme
    elevations. Please discuss your basis for such claims."

  WHY THIS MATTERS FOR CHECK 4: Curanex compared its preclinical
  drug directly to an FDA-approved drug (Rezdiffra) and claimed
  superiority on side effects. This is the most aggressive form
  of comparative claim: preclinical drug vs. approved drug,
  claiming the preclinical drug is BETTER. The SEC asked for
  "basis" but the subtext is clear â€” there can be no basis
  because the drug has no human data.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
THE UNDERLYING SEC CONCERN (synthesized):
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  SPECTRUM OF COMPARATIVE LANGUAGE (least to most aggressive):

  1. FACTUAL MECHANISTIC DISTINCTION (generally permitted):
     "ARD-101 targets the X receptor. Existing therapies target
     the Y receptor."
     â†’ Describes a difference without claiming superiority.
     â†’ Permitted IF it does not imply clinical advantage.

  2. "DIFFERENTIATED" (borderline):
     "ARD-101 offers a differentiated mechanism of action."
     â†’ Implies the difference is clinically meaningful.
     â†’ Not explicitly challenged in comment letters but sits
       between #1 and #3.

  3. "POTENTIAL BEST-IN-CLASS" (challenged â€” Nuvalent):
     â†’ "Potential" does NOT cure "best-in-class."
     â†’ SEC required deletion.

  4. "SAFER" / "MORE EFFECTIVE" with "we believe" (challenged
     â€” Zenas):
     â†’ "We believe" does NOT cure comparative safety/efficacy.
     â†’ SEC explicitly said qualifying language doesn't help.

  5. "SUPERIOR" / "BOASTS SUPERIOR" with named competitor
     (challenged â€” Curanex):
     â†’ Direct superiority claim against a specific FDA-approved
       drug by a preclinical company. Most aggressive.

  KEY RULE: If the comparison implies clinical superiority and
  there is no head-to-head clinical data, the SEC will challenge
  it regardless of hedging language.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
HOW THIS CHECK WAS PROCESSED:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  Script: s1_parser.py â†’ _scan_comparative()

  Regex COMPARATIVE_RE scans for:
  - "best-in-class", "first-in-class"
  - "superior", "differentiated"
  - "safer", "more effective", "less toxic"
  - "outperform", "advantage over"
  - "unlike [drug name]", "compared to [drug name]"

  For each hit:
  1. Extract 400-char context
  2. Check for head-to-head trial citation within 500 chars
  3. Check for named competitor drugs nearby
  4. Classify claim type: MECHANISTIC_DISTINCTION |
     CLINICAL_SUPERIORITY | HEDGED_SUPERIORITY


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
S-1 TEXT FOUND [FOR THE S-1 UNDER REVIEW]:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  "Differentiated" used to describe ARD-101/ARD-201's mechanism
  compared to GLP-1 receptor agonists. No head-to-head clinical
  data cited.

  [PLACEHOLDER â€” exact AARD passage with section and page.]

  Claim type: sits at level #2 on the spectrum â€” mechanistic
  distinction with implied clinical advantage. Less aggressive
  than "best-in-class" or "safer", but Khosla precedent applies.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
ESCALATION TRIGGERED: YES
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  Reason: Comparative language ("differentiated") found without
  head-to-head data. While "differentiated" is less aggressive
  than "best-in-class" or "safer", the Khosla letter shows the
  SEC challenges mechanistic comparisons to named drug classes
  when framed to imply advantage.


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ESCALATION PROMPT DESIGN â€” CHECK 4
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 1: LANGUAGE-ON-SPECTRUM ANALYSIS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

SYSTEM CONTEXT:
  You are reviewing an S-1 registration statement for compliance
  with SEC standards on comparative claims about drug candidates.
  The SEC requires head-to-head clinical data for any claim that
  implies one drug is better than another. You will place the
  S-1's language on a severity spectrum using actual SEC comment
  letters as anchors.

SLOT 1 â€” S-1 PASSAGES WITH COMPARATIVE LANGUAGE:
  [All passages containing comparative terms, with section/page
  and 400-char context.]

SLOT 2 â€” SEC COMMENT LETTER SPECTRUM (anchors from least to
most severe SEC response):

  ANCHOR 1 â€” KHOSLA/VALO HEALTH (mechanistic comparison):
  CHALLENGED TEXT: [comparison to S1P1R functional antagonists]
  SEC RESPONSE: "Please remove the comparison to S1P1R functional
  antagonists unless these antagonists were included in a
  head-to-head clinical trial."
  SEVERITY: Mechanistic comparison â†’ removal unless data exists.

  ANCHOR 2 â€” NUVALENT ("potential best-in-class"):
  CHALLENGED TEXT: "potential best-in-class product candidate[s]"
  on pages 3, 118, 130.
  SEC RESPONSE: "The term 'best-in-class' suggests that the
  product candidates are effective and likely to be approved...
  Given the early stage of development... it is not appropriate
  to suggest that this product is likely to be effective or
  receive regulatory approval. Please delete."
  SEVERITY: "Potential" didn't help â†’ deletion required.

  ANCHOR 3 â€” ZENAS ("safer"/"more effective" with "we believe"):
  CHALLENGED TEXT: obexelimab is "safer" and "more effective"
  than anti-CD20/anti-CD19 therapies.
  SEC RESPONSE: "Qualifying language that statements of safety
  and efficacy are expressions of the company's beliefs or
  expectations do not address this concern."
  SEVERITY: "We believe" explicitly rejected as cure.

  ANCHOR 4 â€” CURANEX (superiority over named FDA-approved drug):
  CHALLENGED TEXT: "Phyto-N boasts superior anti-inflammatory
  properties and unlike recently FDA approved Rezdiffra, Phyto-N
  mitigates inflammation occurrence without causing adverse
  reaction."
  SEC RESPONSE: "Please discuss your basis for such claims."
  SEVERITY: Preclinical drug claiming superiority over approved
  drug â€” most aggressive.

SLOT 3 â€” STRUCTURED ANALYSIS QUESTIONS:

  For each S-1 passage in SLOT 1, answer:

  (a) CLAIM CLASSIFICATION: Where does this language sit on the
      spectrum?
      - Level 1: Factual mechanistic distinction (no implied
        superiority)
      - Level 2: "Differentiated" or similar (implied advantage)
      - Level 3: "Best-in-class" / "first-in-class" (explicit
        category leadership)
      - Level 4: "Safer" / "more effective" / "superior" (direct
        comparative claims)
      - Level 5: Superiority over named competitor (most
        aggressive)

  (b) HEDGING PRESENT: Does the S-1 use qualifying language
      ("we believe", "potential", "designed to")? NOTE: Per the
      Zenas letter, hedging does NOT cure comparative claims.

  (c) DATA SUPPORT: Is there head-to-head clinical data cited?
      - If yes: quote the trial and results
      - If no: note its absence

  (d) NAMED COMPETITORS: Does the passage name specific drugs
      or drug classes? Per the Khosla letter, comparisons to
      named competitors require head-to-head data.

  (e) WHICH ANCHOR IS CLOSEST: Match this passage to the closest
      SEC comment letter anchor and explain why.

  (f) RECOMMENDATION:
      - GREEN: Factual mechanistic distinction without implied
        superiority
      - YELLOW: "Differentiated" or similar borderline language
        â€” not identical to challenged patterns but raises
        questions. Attorney review recommended.
      - RED: Language matching Nuvalent/Zenas/Curanex pattern â€”
        SEC has consistently required deletion or revision.

REQUIRED OUTPUT FORMAT (Step 1):

  {
    "passages_analyzed": [
      {
        "passage_id": 1,
        "section": "[section name]",
        "page_approx": "[page]",
        "comparative_term": "[word/phrase found]",
        "claim_level": 1 | 2 | 3 | 4 | 5,
        "hedging_present": true | false,
        "hedging_text": "[quoted]" | null,
        "head_to_head_data": true | false,
        "named_competitors": ["drug A", "drug class B"] | [],
        "closest_anchor": "KHOSLA" | "NUVALENT" | "ZENAS"
          | "CURANEX",
        "recommendation": "GREEN" | "YELLOW" | "RED",
        "reasoning": "[2-3 sentences]"
      }
    ],
    "total_comparative_claims": 0,
    "claims_with_data": 0,
    "claims_without_data": 0,
    "max_severity_level": 0,
    "step1_assessment": "CLEAR" | "CONCERN" | "SIGNIFICANT_CONCERN"
  }


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 2: WEB SEARCH AUGMENTATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  SEARCH QUERIES:
  1. "SEC comment letter best-in-class differentiated biotech
     2024 2025"
  2. "SEC comment letter comparative claims drug candidate S-1"

  PURPOSE: Check whether "differentiated" has been specifically
  challenged. Any recent letters distinguishing "differentiated"
  from "best-in-class"?

  OUTPUT: Same format as Check 2 Step 2.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 3: FINAL STATUS DETERMINATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  DECISION TREE:

  IF step1_assessment = "CLEAR":
    â†’ ğŸŸ¢ GREEN

  IF step1_assessment = "CONCERN":
    IF max_severity_level <= 2 (factual distinction or
       "differentiated"):
      â†’ ğŸŸ¡ YELLOW
      â†’ Narrative: "'Differentiated' used to describe [drug]'s
        mechanism compared to [competitor class]. Less aggressive
        than 'best-in-class' (Nuvalent) or 'safer/more effective'
        (Zenas). However, Khosla precedent shows SEC challenges
        mechanistic comparisons to named drug classes without
        head-to-head data. Warrants attorney review."
    IF max_severity_level >= 3:
      â†’ ğŸ”´ RED
      â†’ Narrative: "Language matches the pattern challenged in
        [closest anchor]. SEC required deletion/revision in that
        case. [N] instances without supporting data."

  IF step1_assessment = "SIGNIFICANT_CONCERN":
    â†’ ğŸ”´ RED
    â†’ Narrative: "Multiple comparative claims at severity level
      [N], matching [anchor(s)]. SEC has consistently required
      deletion. No head-to-head data cited."

  OUTPUT: Same JSON format as Check 2 Step 3.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
FOR THE CURRENT S-1 (AARD): ESCALATION RESULT
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  Passage analyzed: "differentiated" describing ARD-101/ARD-201
  mechanism vs. GLP-1 receptor agonists.

  Claim level: 2 (implied advantage, not explicit superiority).
  Hedging: [check if "we believe" or "potential" present].
  Head-to-head data: No.
  Named competitors: GLP-1 receptor agonists (drug class, not
  individual drug).
  Closest anchor: KHOSLA (mechanistic comparison to drug class).

  Status After Escalation: ğŸŸ¡ YELLOW

  Key Finding: "Differentiated" is less aggressive than
  "best-in-class" or "safer/more effective" but absent head-to-
  head data, the Khosla precedent applies. Warrants attorney
  review of whether the framing implies clinical superiority.


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
CHECK 5: FDA COMMUNICATIONS
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

LAW / STANDARD BEING CHECKED:

  When a company discloses FDA interactions, it must present a
  BALANCED picture. Two distinct sub-issues:

  (A) SELECTIVE DISCLOSURE: Disclosing positive FDA feedback
      (breakthrough therapy, fast track, positive pre-IND meeting)
      while omitting negative feedback (clinical hold, CRL,
      additional trial requirements) is the pattern that led to
      fraud charges in SEC v. AVEO Pharmaceuticals. Tongue v.
      Sanofi held that material FDA feedback â€” especially
      negative â€” must be disclosed when important to investors.

  (B) IMPLYING APPROVAL LIKELIHOOD: Using FDA interactions to
      suggest approval is more likely ("efficient regulatory
      pathway", "established endpoints", "FDA guidance supports
      NDA submission") without adequate cautionary language. The
      SEC has challenged this pattern in Aerovate and Annovis Bio.

  Section 11 of the Securities Act: Liability for misleading
  statements in registration statements.

  Rule 408: Affirmative obligation to disclose material
  information necessary to prevent statements from being
  misleading.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
SOURCES / AUTHORITIES
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

ENFORCEMENT ACTION: SEC v. AVEO PHARMACEUTICALS (2018)

  WHAT HAPPENED: AVEO selectively disclosed positive FDA feedback
  about its cancer drug tivozanib while omitting that the FDA
  had told the company in an end-of-Phase-2 meeting that it would
  need to conduct an additional clinical trial â€” a material
  negative fact that would have signaled to investors that the
  development timeline was longer and approval less certain.

  SEC charged AVEO with fraud for the selective disclosure. The
  complaint alleged that the company's Chief Medical Officer made
  materially misleading statements by presenting a one-sided
  picture of FDA interactions.

  SEC COMPLAINT (filed Sep. 1, 2016):

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/divisions/enforce/claims/docs/
    aveo-complaint-090116.pdf

    Key passages from the complaint describing:
    (a) What positive FDA feedback AVEO disclosed
    (b) What negative FDA feedback AVEO omitted
    (c) Why the SEC considered this fraudulent

    NEED: Specific paragraphs from complaint detailing the
    selective disclosure pattern.]

  SEC LITIGATION RELEASE (LR-24062, 2018):

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/enforcement-litigation/distributions-
    harmed-investors/sec-v-aveo-pharmaceuticals-inc-et-al-case-
    no-16-cv-10607-d-mass

    NEED: Summary of charges, outcome, penalties.]

  KEY PATTERN: The violation was NOT that AVEO lied about FDA
  feedback. It was that AVEO told HALF the story â€” the positive
  half. The omission of the negative half made the positive
  disclosure misleading.

  WHY THIS MATTERS: AVEO is the ceiling case for FDA
  communications violations. It shows what happens at the extreme
  end â€” fraud charges. The check is designed to catch the pattern
  BEFORE it becomes an AVEO-level problem.


CASE LAW: TONGUE v. SANOFI, 816 F.3d 199 (2d Cir. 2016)

  HOLDING: Material FDA feedback â€” especially negative â€” must be
  disclosed when important to investors. The Second Circuit held
  that Sanofi's failure to disclose negative FDA communications
  about its MS drug lemtrada was actionable under securities
  fraud law.

  [PLACEHOLDER â€” FETCH FROM:
  https://www.stblaw.com/about-us/publications/view/2024/01/23/
  second-circuit-decides-two-matters-of-first-impression-
  concerning-challenged-statements-on-scientific-studies-and-
  data-interpretation

  NEED: Key holdings from the case, especially:
  (a) What the duty to disclose FDA communications is
  (b) When negative FDA feedback becomes material
  (c) How the court balanced selective disclosure]

  KEY PATTERN: The duty is not just to avoid lying about FDA
  interactions â€” it's to avoid painting a misleadingly positive
  picture by omitting the negative.


SEC COMMENT LETTER: AEROVATE THERAPEUTICS (S-1, filed ~Jun. 2021)

  S-1 TEXT THAT WAS CHALLENGED:

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/Archives/edgar/data/1798749/
    000110465921078871/tm2114556-3_s1.htm

    Known from comment letter:
    (a) "received regulatory guidance from the FDA that your
    clinical program could support a NDA submission"
    (b) "pursuing an efficient clinical development program
    utilizing established endpoints for development and approval
    of previous PAH drugs"

    NEED: Full surrounding paragraphs with section/page.]

  SEC COMMENT LETTER (Jun. 2, 2021):

    "We note your statement that you have received regulatory
    guidance from the FDA that your clinical program could support
    a NDA submission. Please revise to provide context for such
    statement and balance your disclosure by stating that the
    process of clinical development is inherently uncertain and
    there can be no guarantee that you will obtain marketing
    approval. We also note your statements that your 'focus on
    developing AV-101 is driven by promising historical results
    from the Phase 3 IMPRES clinical trial of oral imatinib,'
    that you are 'pursuing an efficient clinical development
    program utilizing established endpoints for development and
    approval of previous PAH drugs' and similar statements
    throughout the registration statement. These statements could
    imply that the FDA has approved, or will more easily approve,
    your product candidate."

  WHAT THE SEC CHALLENGED:
  - "FDA guidance... could support NDA submission" â€” selective
    positive disclosure without balancing with uncertainty.
  - "efficient clinical development program" â€” implies a faster/
    easier path to approval.
  - "established endpoints" â€” implies the FDA has pre-approved
    the development program.

  KEY PATTERN: The SEC's concern is NOT that the company disclosed
  FDA interactions. It's that the framing implied approval was
  more likely or the path was easier than it actually is.


SEC COMMENT LETTER: ANNOVIS BIO (S-1, filed ~Jun. 2019)

  S-1/10-K TEXT THAT WAS CHALLENGED:

    [PLACEHOLDER â€” FETCH FROM:
    https://www.sec.gov/Archives/edgar/data/1477845/
    000110465923040275/anvs-20221231x10k.htm

    Known from comment letter:
    (a) "expect our lead compound to be efficacious" (p.1)
    (b) "expect to obtain FDA approval in 2024" (p.2)
    (c) "clinical studies and preclinical data have established
    and/or proven the safety or efficacy" (p.3)

    NEED: Full surrounding paragraphs with section/page.]

  SEC COMMENT LETTER (Jun. 21, 2019):

    "We note your disclosure that you expect your lead compound
    to be efficacious and that you showed in studies that ANVS-401
    was safe on page 1, that you expect to obtain FDA approval in
    2024 on page 2 and that clinical studies and preclinical data
    have established and/or proven the safety or efficacy of
    ANVS-401 on page 3. As your product candidate has not
    received FDA approval, it is premature to suggest or imply
    that it is safe or effective. Also, there can be no certainty
    as to when or if you will receive FDA approval."

  WHAT THE SEC CHALLENGED:
  - "expect to obtain FDA approval in 2024" â€” projecting a
    specific approval date. The SEC said there can be "no
    certainty as to when or if."
  - "established and/or proven the safety or efficacy" â€” the
    strongest possible safety/efficacy language, used before
    approval. This straddles Check 3 (preclinical framing) and
    Check 5 (implying approval likelihood).

  KEY PATTERN: The most aggressive version â€” projecting a
  specific approval date AND claiming safety/efficacy is
  "established and/or proven." The SEC's response was
  categorical: "it is premature to suggest or imply."


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
THE UNDERLYING SEC CONCERN (synthesized):
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  TWO TESTS for FDA communication compliance:

  TEST 1 â€” BALANCE: Are BOTH positive AND negative FDA
  interactions disclosed?
  - Positive only: FAIL (AVEO pattern â†’ potential fraud)
  - Positive in Business + Negative in Risk Factors only:
    BORDERLINE (segregation may reduce visibility of negative)
  - Both in same section (e.g., BUSINESS): PASS

  TEST 2 â€” FRAMING: Does the disclosure imply approval is more
  likely or the path is easier?
  - "FDA guidance supports NDA submission" without uncertainty
    language: FAIL (Aerovate pattern)
  - "Expect FDA approval in [year]": FAIL (Annovis pattern)
  - "FDA granted Orphan Drug Designation" with "there can be no
    assurance that we will receive marketing approval": PASS

  SECTION PLACEMENT MATTERS: Positive FDA news in the Prospectus
  Summary or Business section + negative FDA news buried in Risk
  Factors = the SEC may treat this as unbalanced. Best practice:
  positive and negative in the SAME section, or at least
  cross-referenced.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
HOW THIS CHECK WAS PROCESSED:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  Script: s1_parser.py â†’ _scan_fda_language()

  STEP A â€” FDA REFERENCE SCAN:
  FDA_RE regex finds all passages mentioning FDA interactions:
  "FDA", "Food and Drug Administration", "IND", "NDA", "BLA",
  "orphan drug", "fast track", "breakthrough therapy",
  "priority review", "accelerated approval", "clinical hold",
  "complete response letter", "refuse to file"

  STEP B â€” SECTION CLASSIFICATION:
  _classify_section() determines where each FDA reference appears:
  SUMMARY, BUSINESS, RISK_FACTORS, MD&A, GOVERNMENT_REGULATION

  STEP C â€” TONE CLASSIFICATION:
  Each FDA passage classified as:
  - POSITIVE: breakthrough therapy, fast track, orphan drug,
    "FDA agreed", "FDA guidance supports", special protocol
    assessment
  - NEGATIVE: clinical hold, CRL, refuse to file, "FDA required
    additional", "FDA noted concerns", denial of designation
  - NEUTRAL: general regulatory process description, standard
    risk factor language

  STEP D â€” BALANCE ASSESSMENT:
  - positive > 0 AND negative = 0 â†’ RED (selective disclosure)
  - positive in BUSINESS, negative ONLY in RISK_FACTORS â†’
    YELLOW (segregated disclosure)
  - positive and negative in same section(s) â†’ GREEN (balanced)
  - negative > 0 AND positive = 0 â†’ GREEN (conservative)

  STEP E â€” FRAMING CHECK:
  For each POSITIVE passage, check for nearby uncertainty
  language:
  - "no assurance" / "no guarantee" / "inherently uncertain"
  - "there can be no certainty" / "does not guarantee approval"
  If positive FDA disclosure WITHOUT uncertainty caveat â†’
  ESCALATE (Aerovate pattern).


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
S-1 TEXT FOUND [FOR THE S-1 UNDER REVIEW]:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  POSITIVE FDA INTERACTIONS:
  - Orphan Drug Designation granted for PWS (BUSINESS section)
    [PLACEHOLDER â€” exact quote with page]

  NEGATIVE FDA INTERACTIONS:
  - Breakthrough Therapy designation denied â€” "the FDA noted
    that we would need to provide additional information"
    (BUSINESS section)
    [PLACEHOLDER â€” exact quote with page]

  SECTION PLACEMENT: Both positive and negative disclosed in
  BUSINESS section. Not segregated â€” positive and negative
  appear in the same narrative flow.

  BALANCE ASSESSMENT: Balanced. Both positive and negative in
  same section.

  FRAMING CHECK: Orphan Drug Designation is a factual statement
  ("FDA granted..."). Not framed to imply approval is more
  likely. Breakthrough Therapy denial is disclosed with context.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
ESCALATION TRIGGERS:
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  TRIGGER 1: Positive > 0 AND Negative = 0 â†’ RED, ESCALATE.
  (Potential AVEO pattern â€” selective disclosure.)

  TRIGGER 2: Positive in BUSINESS, Negative ONLY in RISK_FACTORS
  â†’ YELLOW, ESCALATE.
  (Segregated disclosure â€” less severe than omission but still
  problematic.)

  TRIGGER 3: Positive FDA disclosure WITHOUT uncertainty caveat
  â†’ ESCALATE.
  (Aerovate pattern â€” implying approval likelihood.)

  TRIGGER 4: Specific approval date projected â†’ RED, ESCALATE.
  (Annovis pattern â€” "expect FDA approval in [year]".)

  NO TRIGGER: Balanced disclosure, same section placement,
  adequate uncertainty language â†’ GREEN.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
SATISFIED: Yes â€” balanced, same-section placement. No escalation.
STATUS: ğŸŸ¢ GREEN
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
ESCALATION PROMPT DESIGN â€” CHECK 5
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 1: BALANCE AND FRAMING ANALYSIS
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

SYSTEM CONTEXT:
  You are reviewing an S-1 registration statement for compliance
  with SEC standards on FDA communication disclosure. The SEC
  requires balanced presentation of FDA interactions. Selective
  disclosure of positive feedback while omitting negative feedback
  led to fraud charges in SEC v. AVEO Pharmaceuticals. Framing
  that implies approval is more likely was challenged in Aerovate
  and Annovis Bio. You will analyze the S-1's FDA disclosures
  against these authorities.

SLOT 1 â€” ALL FDA-RELATED PASSAGES FROM THE S-1:
  [Every passage mentioning FDA, organized by section.
  Each passage tagged as POSITIVE, NEGATIVE, or NEUTRAL.
  Section location noted.]

SLOT 2 â€” AUTHORITIES:

  ENFORCEMENT â€” AVEO (selective disclosure â†’ fraud):
  "AVEO selectively disclosed positive FDA feedback about
  tivozanib while omitting that the FDA had recommended an
  additional clinical trial. SEC charged fraud."
  [PLACEHOLDER â€” specific complaint paragraphs when fetched]

  CASE LAW â€” TONGUE v. SANOFI (duty to disclose negative):
  "Material FDA feedback â€” especially negative â€” must be
  disclosed when important to investors."
  [PLACEHOLDER â€” specific holdings when fetched]

  COMMENT LETTER â€” AEROVATE (implying approval likelihood):
  "We note your statement that you have received regulatory
  guidance from the FDA that your clinical program could support
  a NDA submission. Please revise to provide context... These
  statements could imply that the FDA has approved, or will more
  easily approve, your product candidate."

  COMMENT LETTER â€” ANNOVIS BIO (projected approval date):
  "We note your disclosure that you expect to obtain FDA approval
  in 2024... there can be no certainty as to when or if you will
  receive FDA approval."

SLOT 3 â€” STRUCTURED ANALYSIS QUESTIONS:

  (a) BALANCE TEST: List all positive and all negative FDA
      interactions disclosed. Is the picture balanced?
      - Count: [N] positive, [N] negative, [N] neutral
      - If positive > 0 and negative = 0: "AVEO RISK â€” selective
        disclosure pattern detected"

  (b) SECTION PLACEMENT: Where are positive vs. negative
      disclosures located?
      - Both in same section â†’ BALANCED
      - Positive in Summary/Business, negative only in Risk
        Factors â†’ SEGREGATED
      - Positive only, no negative anywhere â†’ OMITTED

  (c) FRAMING TEST: For each positive FDA disclosure, does it:
      - State a fact ("FDA granted Orphan Drug Designation") â†’
        OK
      - Imply approval likelihood ("FDA guidance supports NDA
        submission") â†’ AEROVATE RISK
      - Project timeline ("expect FDA approval in [year]") â†’
        ANNOVIS RISK

  (d) UNCERTAINTY LANGUAGE: For each positive FDA disclosure,
      is there nearby uncertainty language?
      - "No assurance", "no guarantee", "inherently uncertain"
      - If absent: flag the passage

  (e) SEVERITY ASSESSMENT:
      - AVEO-LIKE: Positive disclosed, negative omitted entirely
        (MOST SEVERE â€” potential fraud)
      - AEROVATE-LIKE: Positive framed to imply approval
        likelihood without adequate uncertainty (MODERATE)
      - ANNOVIS-LIKE: Specific approval date projected (MODERATE)
      - BALANCED: Both positive and negative disclosed with
        adequate framing (CLEAR)

REQUIRED OUTPUT FORMAT (Step 1):

  {
    "fda_disclosures": {
      "positive": [
        {
          "passage_id": 1,
          "section": "[section name]",
          "content_summary": "[1 sentence]",
          "implies_approval_likelihood": true | false,
          "uncertainty_caveat_nearby": true | false,
          "projects_timeline": true | false
        }
      ],
      "negative": [
        {
          "passage_id": 2,
          "section": "[section name]",
          "content_summary": "[1 sentence]"
        }
      ],
      "neutral": []
    },
    "balance_test": "BALANCED" | "SEGREGATED" | "OMITTED",
    "framing_concerns": [
      {
        "passage_id": 1,
        "concern_type": "AEROVATE_LIKE" | "ANNOVIS_LIKE",
        "reasoning": "[1-2 sentences]"
      }
    ],
    "severity": "AVEO_LIKE" | "AEROVATE_LIKE" | "ANNOVIS_LIKE"
      | "BALANCED",
    "step1_assessment": "CLEAR" | "CONCERN" | "SIGNIFICANT_CONCERN"
  }


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 2: WEB SEARCH AUGMENTATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  SEARCH QUERIES:
  1. "SEC comment letter FDA communications selective disclosure
     biotech 2024 2025"
  2. "SEC enforcement selective FDA disclosure S-1 registration"

  PURPOSE: Has there been any enforcement action or comment
  letter post-AVEO on selective FDA disclosure? Any updated
  guidance?

  OUTPUT: Same format as Check 2 Step 2.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
STEP 3: FINAL STATUS DETERMINATION
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  DECISION TREE:

  IF step1_assessment = "CLEAR" (balanced):
    â†’ ğŸŸ¢ GREEN

  IF step1_assessment = "CONCERN":
    IF balance_test = "SEGREGATED":
      â†’ ğŸŸ¡ YELLOW
      â†’ Narrative: "Positive FDA interactions in Business section,
        negative interactions only in Risk Factors. While not
        omitted, the segregation may reduce visibility. AVEO
        precedent suggests balanced same-section disclosure is
        best practice. Attorney review recommended."
    IF framing_concerns present (Aerovate/Annovis patterns):
      â†’ ğŸŸ¡ YELLOW
      â†’ Narrative: "[Passage] implies approval likelihood without
        adequate uncertainty language. Matches Aerovate/Annovis
        pattern. Attorney review recommended."

  IF step1_assessment = "SIGNIFICANT_CONCERN":
    IF balance_test = "OMITTED" (positive only, no negative):
      â†’ ğŸ”´ RED
      â†’ Narrative: "S-1 discloses [N] positive FDA interactions
        but NO negative interactions. This matches the AVEO
        selective disclosure pattern that led to fraud charges.
        SEC v. AVEO established that omitting material negative
        FDA feedback while disclosing positive feedback is
        fraudulent. Immediate attorney review required."
    IF projects_timeline = true:
      â†’ ğŸ”´ RED
      â†’ Narrative: "S-1 projects specific FDA approval date
        ('[year]'). Per the Annovis letter, 'there can be no
        certainty as to when or if you will receive FDA approval.'
        Revision required."

  OUTPUT: Same JSON format as Check 2 Step 3.


â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
FOR THE CURRENT S-1 (AARD): NO ESCALATION TRIGGERED
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€

  Balance test: BALANCED â€” positive (Orphan Drug Designation)
  and negative (Breakthrough Therapy denied) both in BUSINESS
  section.

  Framing test: Orphan Drug Designation stated as fact, not
  framed to imply approval likelihood. No projected approval
  date.

  Status: ğŸŸ¢ GREEN

  Key Finding: FDA interactions balanced â€” Orphan Drug
  Designation (positive) and Breakthrough Therapy denial
  (negative) both disclosed in BUSINESS section without
  selective emphasis.


â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•
PLACEHOLDER TRACKER â€” S-1 TEXT STILL NEEDED
â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•

The following challenged S-1 passages need to be fetched to
complete the comparison pairs:

CHECK 3:
  â–¡ Curanex S-1: Full paragraphs containing "promising efficacy
    in animal models" and "boasts superior anti-inflammatory"
    SOURCE: https://www.sec.gov/Archives/edgar/data/2025942/
    000149315224041335/forms-1.htm

  â–¡ Virpax S-1: Full paragraphs containing "pain control for up
    to 96 hours" and "comparable preclinical activity to morphine"
    SOURCE: https://www.sec.gov/Archives/edgar/data/1708331/
    000101376224002110/ea0209752-s1_virpaxphar.htm

CHECK 4:
  â–¡ Nuvalent S-1: Full paragraphs from pages 3, 118, 130
    containing "potential best-in-class"
    SOURCE: https://www.sec.gov/Archives/edgar/data/1861560/
    000119312521209001/d174530ds1.htm

  â–¡ Zenas S-1: Full paragraphs containing "safer" and "more
    effective" re: obexelimab
    SOURCE: https://www.sec.gov/Archives/edgar/data/1953926/
    000110465924091950/tm2332800-11_s1.htm

  â–¡ Khosla/Valo Health S-4: Full paragraphs containing
    comparison to S1P1R functional antagonists
    SOURCE: [need EDGAR URL]

CHECK 5:
  â–¡ AVEO complaint: Key paragraphs describing selective
    disclosure pattern
    SOURCE: https://www.sec.gov/divisions/enforce/claims/docs/
    aveo-complaint-090116.pdf

  â–¡ Tongue v. Sanofi: Key holdings
    SOURCE: https://www.stblaw.com/about-us/publications/view/
    2024/01/23/second-circuit-decides-two-matters-of-first-
    impression-concerning-challenged-statements-on-scientific-
    studies-and-data-interpretation

  â–¡ Aerovate S-1: Full paragraphs containing "FDA guidance...
    could support NDA submission" and "efficient clinical
    development program"
    SOURCE: https://www.sec.gov/Archives/edgar/data/1798749/
    000110465921078871/tm2114556-3_s1.htm

  â–¡ Annovis Bio 10-K: Full paragraphs containing "expect FDA
    approval in 2024" and "established and/or proven"
    SOURCE: https://www.sec.gov/Archives/edgar/data/1477845/
    000110465923040275/anvs-20221231x10k.htm

  â–¡ AARD S-1: All quoted passages referenced in Checks 3, 4, 5
    above (preclinical references, "differentiated" passage,
    FDA interaction passages)
